In vitro anti-tumor activity of anti-c-erbB-2 x anti-CD3 epsilon bifunctional monoclonal antibody.
With the aim of developing an effective cancer immunotherapy for common epithelial cancer, a new class of bifunctional antibody (BFA) was developed; one arm of this BFA recognized c-erbB-2 gene product, and the other arm recognized CD3 epsilon, a T-cell specific surface antigen. Application of this BFA with human peripheral blood lymphocytes exhibited specific anti-tumor activity in vitro on a breast tumor cell line, ZR-75-1, which expressed abundant c-erbB-2 gene product on its cell surface. These results indicate that BFA recognizing an oncogene product on cell surface is a potential new agent for cancer immunotherapy.
Viral Diseases Research Division, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd.
Y
Y
Sugiyama
M
M
Aihara
M
M
Shibamori
K
K
Deguchi
K
K
Imagawa
M
M
Kikuchi
H
H
Momota
T
T
Azuma
H
H
Okada
O
O
Alper
D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000737:chemistry / Q000627:therapeutic use*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D017252:CD3 Complex; D003432:Cross-Linking Reagents; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007111:Immunity, Cellular; D007140:Immunoglobulin Fab Fragments / Q000737:chemistry / Q000627:therapeutic use; D066298:In Vitro Techniques; D011518:Proto-Oncogene Proteins / Q000276:immunology*; D018719:Erb-b2 Receptor Tyrosine Kinases; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D003432:Cross-Linking Reagents; D007140:Immunoglobulin Fab Fragments; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011948:Receptors, Antigen, T-Cell